(UroToday.com) In the double-blind placebo-controlled ACIS study, investigator-assessed radiographic progression-free survival (rPFS) was significantly improved with apalutamide + abiraterone acetate + prednisone versus placebo + abiraterone acetate + prednisone in chemotherapy-naive mCRPC, with no significant new safety signals. Among prespecified subgroups, efficacy and safety were explored in two difficult to treat subgroups: patients with visceral disease (liver, lung, and/or adrenal gland metastasis) or age ≥ 75 years. At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Fred Saad and colleagues presented the results of these two key subgroups of the ACIS trial.